Literature DB >> 11040129

Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle.

P Massimi1, L Banks.   

Abstract

The human papillomavirus type 16 encodes two principal oncoproteins, E6 and E7. The E7 protein has been shown to deregulate the cell cycle through interactions with a variety of proteins involved in cell cycle control and transcriptional regulation. These activities result in E7 being able to cooperate with activated oncogenes in the transformation of primary rodent cells, and with the viral E6 protein during human keratinocyte immortalization. Although a large number of activities have been ascribed to the E7 protein, little is known about its regulation during the cell cycle. We have performed a series of studies to investigate potential changes in E7 phosphorylation during the cell cycle and we show that E7 is indeed differentially phosphorylated. Casein kinase II is the principal kinase during the early part of the cell cycle, but this activity decreases rapidly as cells progress toward S phase. In addition, E7 is transiently phosphorylated at Ser71 in S phase by another, as yet unknown, kinase. These results demonstrate differential regulation of the E7 protein during the cell cycle that most likely represents a means of providing specificity to E7's activities. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040129     DOI: 10.1006/viro.2000.0514

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex.

Authors:  Sharof Tugizov; Jennifer Berline; Rossana Herrera; Maria Elena Penaranda; Mayumi Nakagawa; Joel Palefsky
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.

Authors:  Andriy G Golub; Volodymyr G Bdzhola; Yaroslav V Kyshenia; Vladislav M Sapelkin; Andriy O Prykhod'ko; Olexander P Kukharenko; Olga V Ostrynska; Sergiy M Yarmoluk
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

Review 4.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

5.  Regulation of the human papillomavirus oncoproteins by differential phosphorylation.

Authors:  P Massimi; D Pim; C Kühne; L Banks
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

6.  The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb.

Authors:  Ariane L Jansma; Maria A Martinez-Yamout; Rong Liao; Peiqing Sun; H Jane Dyson; Peter E Wright
Journal:  J Mol Biol       Date:  2014-11-01       Impact factor: 5.469

7.  The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.

Authors:  Kwang-Jin Oh; Anna Kalinina; Jing Wang; Keiko Nakayama; Keiichi I Nakayama; Srilata Bagchi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 8.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

9.  Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes.

Authors:  Nicholas J Genovese; N Sanjib Banerjee; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

Review 10.  The human papillomavirus E7 oncoprotein.

Authors:  Margaret E McLaughlin-Drubin; Karl Münger
Journal:  Virology       Date:  2008-11-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.